|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
The gene encoding the phase I enzyme cytochrome P4502D6 (CYP2D6) has been previously investigated for its potential predictive role in the efficacy of breast cancer treatments such as tamoxifen, but its role in breast cancer susceptibility is unclear.
|
21527579 |
2011 |
|
Malignant Neoplasms
|
0.010 |
GeneticVariation
|
group |
BEFREE |
The results indicated that there is a 3-fold increase in risk of developing this cancer in the presence of one copy of the variant CYP2D6 (HEM) allele and null GSTT1.
|
15588859 |
2005 |
|
Catalepsy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Selective inhibition and induction of brain, but not liver, CYP2D decreased and increased catalepsy after acute haloperidol, respectively.
|
28454738 |
2017 |
|
Depressive disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
The activity of brain and liver cytochrome P450 2D (CYP2D) is differently affected by antidepressants in the chronic mild stress (CMS) model of depression in the rat.
|
30195732 |
2018 |
|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
The simulated diabetes in CYP2D poor metabolizers showed reduced metabolic ratios for M1 enantiomers.
|
30502451 |
2019 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
The simulated diabetes in CYP2D poor metabolizers showed reduced metabolic ratios for M1 enantiomers.
|
30502451 |
2019 |
|
Gilbert Disease (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Gilbert's syndrome, a genetic deficiency in bilirubin UDP-glucuronosyltransferase (UGT1A1), may dispose to increased toxicity of propafenone in poor metabolizers (PMs) of cytochrome P4502D6 because glucuronidation of propafenone is the major metabolic pathway for drug elimination in PMs.
|
10850406 |
2000 |
|
Lung Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Comparisons of CYP2D messenger RNA splice variant profiles in human lung tumors and normal tissues.
|
9205060 |
1997 |
|
Obesity
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
EMA effectively resolves particularly challenging alignments in genomic regions that contain nearby homologous elements, uncovering variants in the pharmacogenomically important CYP2D region, and clinically important genes C4 (schizophrenia) and AMY1A (obesity), which go undetected by existing methods.
|
30138581 |
2018 |
|
Caffeine related disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
The five probe substrates were caffeine (2 mg/kg), bupropion (30 mg/kg), omeprazole (4 mg/kg), dextromethorphan (40 mg/kg), and midazolam (2 mg/kg) for CYP1A, CYP2B, CYP2C, CYP2D, and CYP3A, respectively.
|
29550976 |
2018 |
|
Malignant Head and Neck Neoplasm
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
However, the combinations of CYP1A1 (AA) and CYP2D6 (CC) genotypes decreased risk of HNC (OR 0.20; P = 0.006).
|
24449363 |
2014 |
|
Depressed mood
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The activity of brain and liver cytochrome P450 2D (CYP2D) is differently affected by antidepressants in the chronic mild stress (CMS) model of depression in the rat.
|
30195732 |
2018 |
|
Amelogenesis Imperfecta, Type IB
|
0.010 |
Biomarker
|
disease |
BEFREE |
Liver Kidney Microsomal autoantibody type 1(LKM1) directed to cytochrome P4502D6 (CYP2D6) characterises autoimmune hepatitis type-2 (AIH-2), but is also found in a proportion of chronic hepatitis C virus (HCV) infected patients, CYP2D6252-271 being a major B- cell autoepitope.
|
15000871 |
2004 |
|
Non-alcoholic Fatty Liver Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
This study aims to evaluate the possible pharmacokinetic changes in NAFLD as a result of reduced metabolic activity of CYP2D.
|
30786957 |
2019 |
|
Neurodegenerative Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Alternative splicing patterns of CYP2D genes in human brain and neurodegenerative disorders.
|
10534269 |
1999 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The gene encoding the phase I enzyme cytochrome P4502D6 (CYP2D6) has been previously investigated for its potential predictive role in the efficacy of breast cancer treatments such as tamoxifen, but its role in breast cancer susceptibility is unclear.
|
21527579 |
2011 |
|
Attention deficit hyperactivity disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Atomoxetine is a treatment for attention-deficit/hyperactivity disorder and is primarily eliminated via cytochrome P4502D6 (CYP2D6).
|
12621383 |
2003 |
|
Primary malignant neoplasm
|
0.010 |
GeneticVariation
|
group |
BEFREE |
The results indicated that there is a 3-fold increase in risk of developing this cancer in the presence of one copy of the variant CYP2D6 (HEM) allele and null GSTT1.
|
15588859 |
2005 |
|
Lewy Body Variant of Alzheimer Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Association of CYP2D microsatellite polymorphism with Lewy body variant of Alzheimer's disease.
|
9633694 |
1998 |
|
CYP2D6 polymorphism
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Taking this new information into account, we have reconsidered the potential influence of CYP2D6 polymorphism in lung cancer susceptibility by performing a comparative analysis of the overall mutational spectrum of CYP2D6 and of the rearrangements of CYP2D in 249 patients with lung cancer and in 265 control individuals matched on age, sex, hospital and residence area.
|
9511176 |
1998 |
|
Treatment-resistant schizophrenia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A patient with treatment-resistant schizophrenia and cytochrome P4502D6 gene duplication.
|
11940091 |
2002 |
|
Head and Neck Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
However, the combinations of CYP1A1 (AA) and CYP2D6 (CC) genotypes decreased risk of HNC (OR 0.20; P = 0.006).
|
24449363 |
2014 |
|
Autoimmune hepatitis type 2
|
0.010 |
Biomarker
|
disease |
BEFREE |
Liver Kidney Microsomal autoantibody type 1(LKM1) directed to cytochrome P4502D6 (CYP2D6) characterises autoimmune hepatitis type-2 (AIH-2), but is also found in a proportion of chronic hepatitis C virus (HCV) infected patients, CYP2D6252-271 being a major B- cell autoepitope.
|
15000871 |
2004 |
|
Sporadic Parkinson disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Four polymorphic sites (C/T188, C/T2938, G/C4268, G/A1934) in the cytochrome P4502D6 (debrisoquine 4-hydroxylase) gene were investigated for their association with sporadic Parkinson's disease (PD).
|
10210913 |
1999 |
|
Child Development Disorders, Pervasive
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Meta-analysis of GWAS of over 16,000 individuals with autism spectrum disorder highlights a novel locus at 10q24.32 and a significant overlap with schizophrenia.
|
28540026 |
2017 |